CONNECT WITH US
HealthTech

HealthTech

Outro Secures $7M to Build Healthcare’s First Neuroscience-Based Deprescribing Platform

HIT Consultant logo

Published on

Add as a preferred source on Google
Outro Secures $7M to Build Healthcare’s First Neuroscience-Based Deprescribing Platform

Neuroscience-based deprescribing platform Outro announced that it has raised $7M in combined pre-seed and seed financing to establish clinical and technological infrastructure for discontinuing psychiatric medications safely.

The financing syndicate is backed by Listen Ventures, Cake Ventures , Jason Calacanis’s LAUNCH, Actions Capital , Hannah Grey VC , SemperVirens , Brock Recovery Group , Pave Health Ventures , and additional strategic digital health investors.

Outro combines specially trained deprescribing clinicians, evidence-informed hyperbolic tapering protocols, continuous remote patient monitoring, longitudinal psychosocial counseling, and purpose-built software.

Founded by digital health entrepreneur Brandon Goode and clinical researcher Dr. Mark Horowitz, Outro translates specialized psychopharmacology into an outpatient virtual delivery model:

Scientific Foundation: Co-founder Dr. Mark Horowitz is a leading global researcher on psychiatric medication discontinuation whose academic work established the neurobiological basis for hyperbolic tapering—a protocol that reduces drug dosage by progressively smaller increments as doses decrease to account for non-linear serotonin transporter receptor occupancy curves.

The Flagship “Taper Management” Program: Currently live across 14 U.S. states, the platform combines a specialized network of deprescribing-trained clinicians, individualized evidence-informed tapering schedules, continuous remote symptom tracking, and structured psychosocial support.

National Policy Alignment: The funding coincides with federal recognition of deprescribing as a critical care standard. In 2026, the U.S. Department of Health and Human Services (HHS) formally prioritized the development of national evidence-based deprescribing guidelines in collaboration with the American Psychiatric Association (APA) and the American Society of Clinical Psychopharmacology (ASCP).

The $7M capital injection will be deployed expanding Outro’s licensed clinical network to grow its footprint beyond the initial 14-state footprint.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.